Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Pre-analytical practices for routine coagulation tests in European laboratories. A collaborative study from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM).

Kristoffersen AH, Stavelin AV, Ajzner E, Kristensen GBB, Sandberg S, Van Blerk M, Kitchen S, Kesseler D, Woods TAL, Meijer P.

Clin Chem Lab Med. 2019 May 14. pii: /j/cclm.ahead-of-print/cclm-2019-0214/cclm-2019-0214.xml. doi: 10.1515/cclm-2019-0214. [Epub ahead of print]

PMID:
31085743
2.

Joint EFLM-COLABIOCLI recommendation for venous blood sampling.

Simundic AM, Bölenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov H, Kovalevskaya S, Kristensen GB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, De la Salle B, Seipelt C, Sumarac Z, Vermeersch P.

Ann Biol Clin (Paris). 2019 Apr 1;77(2):131-154. doi: 10.1684/abc.2019.1419.

PMID:
30998194
3.

Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer.

Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H.

Neoplasia. 2019 Apr;21(4):353-362. doi: 10.1016/j.neo.2019.01.002. Epub 2019 Mar 8.

4.

5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.

Kristensen G, Strand SH, Røder MA, Berg KD, Toft BG, Høyer S, Borre M, Sørensen KD, Brasso K.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1025. doi: 10.3390/ijms20051025.

5.

Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model.

Lund KV, Simonsen TG, Kristensen GB, Rofstad EK.

Acta Oncol. 2019 Jun;58(6):828-837. doi: 10.1080/0284186X.2019.1580386. Epub 2019 Feb 27.

PMID:
30810443
6.

Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers.

Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H.

Transl Oncol. 2019 Mar;12(3):576-584. doi: 10.1016/j.tranon.2018.12.010. Epub 2019 Jan 17.

7.

Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.

Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW.

Clin Cancer Res. 2019 Apr 1;25(7):2155-2165. doi: 10.1158/1078-0432.CCR-18-2792. Epub 2019 Jan 7.

PMID:
30617134
8.

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators.

Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16.

9.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators.

Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413383
10.

Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only.

Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K.

Int J Gynecol Cancer. 2018 Nov;28(9):1789-1795. doi: 10.1097/IGC.0000000000001356.

PMID:
30365455
11.

Status on fasting definition for blood sampling in the Nordic countries - time for a harmonized definition.

Grankvist K, Sigthorsson G, Kristensen GB, Pelanti J, Nybo M.

Scand J Clin Lab Invest. 2018 Nov - Dec;78(7-8):591-594. doi: 10.1080/00365513.2018.1528503. Epub 2018 Oct 19.

PMID:
30338721
12.

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Flores-Morales A, Bergmann TB, Lavallee C, Batth TS, Lin D, Lerdrup M, Friis S, Bartels A, Kristensen G, Krzyzanowska A, Xue H, Fazli L, Hansen KH, Røder MA, Brasso K, Moreira JM, Bjartell A, Wang Y, Olsen JV, Collins CC, Iglesias-Gato D.

Clin Cancer Res. 2019 Jan 15;25(2):595-608. doi: 10.1158/1078-0432.CCR-18-0729. Epub 2018 Oct 1.

PMID:
30274982
13.

Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.

Kristensen G, Røder MA, Berg KD, Elversang J, Iglesias-Gato D, Moreira J, Toft BG, Brasso K.

APMIS. 2018 Oct;126(10):804-813. doi: 10.1111/apm.12886. Epub 2018 Sep 6.

PMID:
30191621
14.

Joint EFLM-COLABIOCLI Recommendation for venous blood sampling

Simundic AM, Bölenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov H, Kovalevskaya S, Kristensen GBB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, De la Salle B, Seipelt C, Sumarac Z, Vermeersch P; Working Group for Preanalytical Phase (WG-PRE), of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI).

Clin Chem Lab Med. 2018 Nov 27;56(12):2015-2038. doi: 10.1515/cclm-2018-0602. Review.

15.

DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma.

Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1193-1201. doi: 10.1016/j.ijrobp.2018.04.035. Epub 2018 Apr 19.

PMID:
29859790
16.

Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.

Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE.

J Natl Cancer Inst. 2018 Dec 1;110(12):1400-1408. doi: 10.1093/jnci/djy063.

17.

Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples.

Gidske G, Sølvik UØ, Sandberg S, Kristensen GBB.

Clin Chem Lab Med. 2018 Aug 28;56(9):e220-e222. doi: 10.1515/cclm-2018-0193. No abstract available.

PMID:
29630512
18.

Chromatin organisation and cancer prognosis: a pan-cancer study.

Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE.

Lancet Oncol. 2018 Mar;19(3):356-369. doi: 10.1016/S1470-2045(17)30899-9. Epub 2018 Feb 3.

19.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group.

Eur J Surg Oncol. 2019 Jan;45(1):67-74. doi: 10.1016/j.ejso.2017.09.025. Epub 2017 Nov 3. Review.

PMID:
29108961
20.

[Properties of cancer cell DNA affects the prognosis].

Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE.

Tidsskr Nor Laegeforen. 2017 Oct 16;137(19). doi: 10.4045/tidsskr.16.0966. Print 2017 Oct 17. Review. Norwegian.

21.

A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway.

Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A.

Acta Obstet Gynecol Scand. 2017 Oct;96(10):1162-1169. doi: 10.1111/aogs.13199.

PMID:
28795770
22.

Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.

Kristensen G, Berg KD, Lippert S, Christensen IJ, Brasso K, Høyer-Hansen G, Røder MA.

J Clin Pathol. 2017 Dec;70(12):1063-1068. doi: 10.1136/jclinpath-2017-204475. Epub 2017 Jun 12.

PMID:
28607123
23.

Malnutrition related deaths.

Sparre-Sørensen M, Kristensen GN.

Clin Nutr ESPEN. 2016 Oct;15:63-68. doi: 10.1016/j.clnesp.2016.06.001. Epub 2016 Aug 8.

PMID:
28531786
24.

Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer.

Lund KV, Simonsen TG, Kristensen GB, Rofstad EK.

Acta Oncol. 2017 May;56(5):675-681. doi: 10.1080/0284186X.2017.1294762. Epub 2017 Feb 28.

PMID:
28447564
25.

Interpretation of EQA results and EQA-based trouble shooting.

Kristensen GB, Meijer P.

Biochem Med (Zagreb). 2017 Feb 15;27(1):49-62. doi: 10.11613/BM.2017.007. Review.

26.

Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival.

Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I.

Gynecol Oncol. 2017 Jun;145(3):543-548. doi: 10.1016/j.ygyno.2017.03.008. Epub 2017 Mar 27.

PMID:
28356187
27.

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.

Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å.

Dis Markers. 2017;2017:3098542. doi: 10.1155/2017/3098542. Epub 2017 Feb 15.

28.

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G.

Br J Cancer. 2017 Feb 14;116(4):455-463. doi: 10.1038/bjc.2016.435. Epub 2017 Jan 24.

29.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators.

Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18.

PMID:
27871723
30.

L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K.

BMC Cancer. 2016 Aug 4;16:596. doi: 10.1186/s12885-016-2631-4.

31.

Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE).

Cornes M, van Dongen-Lases E, Grankvist K, Ibarz M, Kristensen G, Lippi G, Nybo M, Simundic AM; Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Clin Chem Lab Med. 2017 Jan 1;55(1):27-31. doi: 10.1515/cclm-2016-0426.

32.

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E.

Ann Oncol. 2016 Aug;27(8):1505-10. doi: 10.1093/annonc/mdw238. Epub 2016 Jul 11.

PMID:
27407100
34.

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC.

Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28.

35.

Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.

Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E.

Ann Oncol. 2016 Sep;27(9):1733-9. doi: 10.1093/annonc/mdw236. Epub 2016 Jun 10.

PMID:
27287207
36.

Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients.

Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H.

PLoS One. 2016 May 31;11(5):e0156259. doi: 10.1371/journal.pone.0156259. eCollection 2016.

37.

Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.

Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM.

Am J Clin Pathol. 2016 Apr;145(4):449-58. doi: 10.1093/ajcp/aqw030.

PMID:
27149024
38.

The role of European Federation of Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase in standardization and harmonization of the preanalytical phase in Europe.

Cornes MP, Church S, van Dongen-Lases E, Grankvist K, Guimarães JT, Ibarz M, Kovalevskaya S, Kristensen GB, Lippi G, Nybo M, Sprongl L, Sumarac Z, Simundic AM; Working Group for Preanalytical Phase (WG-PRE) and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Ann Clin Biochem. 2016 Sep;53(Pt 5):539-47. doi: 10.1177/0004563216643969. Epub 2016 May 1. Review.

PMID:
27141012
39.

Chronic obstructive pulmonary disease in Denmark: Age-period-cohort analysis of first-time hospitalisations and deaths 1994-2012.

Lykkegaard J, Kristensen GN.

Respir Med. 2016 May;114:78-83. doi: 10.1016/j.rmed.2016.03.014. Epub 2016 Mar 21.

40.

Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.

Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H.

Clin Cancer Res. 2016 Aug 15;22(16):4067-76. doi: 10.1158/1078-0432.CCR-15-2322. Epub 2016 Mar 24.

41.

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.

Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J.

Lancet Oncol. 2016 Apr;17(4):509-518. doi: 10.1016/S1470-2045(15)00615-4. Epub 2016 Mar 4.

PMID:
26952945
42.

Patient identification and tube labelling - a call for harmonisation.

van Dongen-Lases EC, Cornes MP, Grankvist K, Ibarz M, Kristensen GB, Lippi G, Nybo M, Simundic AM; Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Clin Chem Lab Med. 2016 Jul 1;54(7):1141-5. doi: 10.1515/cclm-2015-1089.

43.

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.

Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A.

Gynecol Oncol. 2016 Mar;140(3):457-62. doi: 10.1016/j.ygyno.2016.01.022. Epub 2016 Jan 22.

PMID:
26807488
44.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
45.

Alzheimer's Disease in the Danish Malnutrition Period 1999-2007.

Sparre-Sørensen M, Kristensen G.

J Alzheimers Dis. 2015;48(4):979-85. doi: 10.3233/JAD-150472.

PMID:
26444789
46.

Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy.

Ruhlmann CH, Iversen TZ, Okera M, Muhic A, Kristensen G, Feyer P, Hansen O, Herrstedt J.

Radiother Oncol. 2015 Nov;117(2):333-7. doi: 10.1016/j.radonc.2015.09.014. Epub 2015 Sep 11.

PMID:
26372344
47.

Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.

Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H.

Epigenetics. 2015;10(10):970-80. doi: 10.1080/15592294.2015.1085140.

48.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

49.

Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer.

Lund KV, Simonsen TG, Hompland T, Kristensen GB, Rofstad EK.

Radiother Oncol. 2015 Jun;115(3):379-85. doi: 10.1016/j.radonc.2015.05.001. Epub 2015 May 18.

PMID:
25998804
50.

Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.

Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J.

Eur J Cancer. 2015 May;51(7):825-32. doi: 10.1016/j.ejca.2015.01.008. Epub 2015 Mar 11.

PMID:
25771433

Supplemental Content

Loading ...
Support Center